Company / Working Capital
ARS Pharmaceuticals, Inc. Working Capital History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$245.8M
FY2025
5-year range
$52.5M / $310.9M
FY2021-FY2025
Trend
-20.9%
vs FY2024
Sector context
#160 of 213
Health Care
What the data says
ARS Pharmaceuticals, Inc.'s working capital of $246M is lower than 75% of companies in the Health Care sector (FY2025). Working Capital has fluctuated over the past 6 years, ranging from $53M in FY2021 to $381M in FY2020.
Based on SEC 10-K filings.
$246M in FY2025 with a 5-year CAGR of -8.4%.
Improved from $229M to $246M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- -3.4%
- 5-Year CAGR
- -8.4%
- 10-Year CAGR
- -
Sector benchmark
Bottom 25% in Health CareTop 75% of 213This company $245.8M Sector average $934.6M
▼
-73.7% below sector average
Key checks
Key Insights
- 5-year CAGR of -8.4%, indicating a declining trend.
- In FY2025, working capital decreased 20.9% year-over-year.
- Ranks #160 out of 213 companies in the Health Care sector.
- Peak working capital was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.44 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $245.8M | -20.9% |
| FY2024 | $310.9M | +35.5% |
| FY2023 | $229.3M | -15.8% |
| FY2022 | $272.3M | +418.2% |
| FY2021 | $52.5M | -86.2% |
| FY2020 | $381.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026